CY1124074T1 - Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων - Google Patents

Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων

Info

Publication number
CY1124074T1
CY1124074T1 CY20211100191T CY211100191T CY1124074T1 CY 1124074 T1 CY1124074 T1 CY 1124074T1 CY 20211100191 T CY20211100191 T CY 20211100191T CY 211100191 T CY211100191 T CY 211100191T CY 1124074 T1 CY1124074 T1 CY 1124074T1
Authority
CY
Cyprus
Prior art keywords
glucocorticoids
relates
glucocorticoid
component
designed
Prior art date
Application number
CY20211100191T
Other languages
English (en)
Inventor
Stanko Skrtic
Jörgen JOHNSSON
Hans Lennernäs
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Shire Viropharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Viropharma Llc filed Critical Shire Viropharma Llc
Publication of CY1124074T1 publication Critical patent/CY1124074T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Η εφεύρεση σχετίζεται με θεραπεία υποκατάστασης γλυκοκορτικοειδών και παρέχει φαρμακευτικές συνθέσεις και κιτ σχεδιασμένα για την παροχή ενός ή περισσοτέρων γλυκοκορτικοειδών σε έναν ασθενή με ανάγκη αυτών με έναν τρόπο που έχει ως αποτέλεσμα επίπεδα ορού του γλυκοκορτικοειδούς που ουσιαστικά μιμούνται εκείνο ενός υγιούς ατόμου για μία κλινικώς ενδεδειγμένη χρονική περίοδο. Η φαρμακευτική σύνθεση περιλαμβάνει ένα ή περισσότερα γλυκοκορτικοειδή, όπου ένα πρώτο τμήμα ενός ή περισσοτέρων γλυκοκορτικοειδών απελευθερώνεται ουσιαστικά άμεσα και ένα δεύτερο τμήμα ενός ή περισσοτέρων γλυκοκορτικοειδών απελευθερώνεται επί ένα παρατεταμένο χρονικό διάστημα τουλάχιστον περίπου 8 ωρών, και η ποσότητα του ενός ή περισσοτέρων γλυκοκορτικοειδών του πρώτου τμήματος, εκφραζόμενα ως ισοδύναμα υδροκορτιζόνης, είναι σε ένα διάστημα από περίπου 15 έως περίπου 50% των συνολικών ισοδυνάμων υδροκορτιζόνης. Η εφεύρεση επίσης σχετίζεται με ένα κιτ που περιλαμβάνει ένα πρώτο και ένα δεύτερο συστατικό, όπου το πρώτο συστατικό είναι σχεδιασμένο για να απελευθερώνει ένα ή περισσότερα γλυκοκορτικοειδή ουσιαστικά άμεσα και το δεύτερο συστατικό είναι σχεδιασμένο για να απελευθερώνει ένα ή περισσότερα γλυκοκορτικοειδή επί ένα παρατεταμένο χρονικό διάστημα τουλάχιστον 8 ωρών. Η εφεύρεση επίσης σχετίζεται με μία μέθοδο αγωγής νόσων που απαιτούν αγωγή με γλυκοκορτικοειδή όπως σε ασθενείς που έχουν μία διαταραχή ανεπάρκειας γλυκοκορτικοειδών. Σε μία άλλη άποψη, η εφεύρεση σχετίζεται με τη χρήση μίας πρώτης και μίας δεύτερης ποσότητας ενός ή περισσοτέρων γλυκοκορτικοειδών για την παρασκευή μίας φαρμακευτικής σύνθεσης ή κιτ για την αγωγή μίας διαταραχής ανεπάρκειας γλυκοκορτικοειδών.
CY20211100191T 2004-04-22 2021-03-05 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων CY1124074T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
EP05735076.1A EP1744730B1 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
PCT/EP2005/004400 WO2005102271A2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy

Publications (1)

Publication Number Publication Date
CY1124074T1 true CY1124074T1 (el) 2022-03-24

Family

ID=35197481

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161101091T CY1118275T1 (el) 2004-04-22 2016-10-26 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων
CY20211100191T CY1124074T1 (el) 2004-04-22 2021-03-05 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161101091T CY1118275T1 (el) 2004-04-22 2016-10-26 Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων

Country Status (26)

Country Link
US (3) US8425937B2 (el)
EP (2) EP1744730B1 (el)
JP (2) JP5149618B2 (el)
CN (2) CN1942176B (el)
AU (1) AU2005235370B2 (el)
BR (1) BRPI0510044B8 (el)
CA (1) CA2564000C (el)
CY (2) CY1118275T1 (el)
DK (2) DK3072507T3 (el)
ES (2) ES2600556T3 (el)
HK (1) HK1179525A1 (el)
HR (2) HRP20161380T1 (el)
HU (2) HUE053248T2 (el)
IL (2) IL178776A (el)
LT (2) LT3072507T (el)
ME (1) ME02584B (el)
MX (2) MX344197B (el)
NZ (1) NZ585340A (el)
PL (2) PL3072507T3 (el)
PT (2) PT1744730T (el)
RS (2) RS61501B1 (el)
SE (1) SE0401031D0 (el)
SG (1) SG188081A1 (el)
SI (1) SI3072507T1 (el)
WO (1) WO2005102271A2 (el)
ZA (1) ZA200609680B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US9925139B2 (en) 2004-04-22 2018-03-27 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
JP2009518405A (ja) * 2005-12-06 2009-05-07 モノソル アールエックス リミテッド ライアビリティ カンパニー 活性物質の送達のための局所フィルム組成物
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
PT2151235E (pt) * 2008-07-21 2011-03-21 Falk Pharma Gmbh Formulação farmacêutica para o tratamento do trato digestivo superior
BRPI1011624A2 (pt) 2009-04-07 2016-03-22 Duocort Pharma Ab composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente.
CN102933218A (zh) 2010-05-20 2013-02-13 杜奥科特药物公司 糖皮质激素基的组合物的剂量学和施用
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
DK2914255T3 (da) 2012-11-02 2021-10-25 Murray & Poole Entpr Ltd Behandling eller forebyggelse af kardiovaskulære hændelser via administration af colchicin
AU2014255434B2 (en) 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
PT2886108T (pt) 2013-12-23 2019-04-01 Dr Falk Pharma Gmbh Formulação farmacêutica otimizada para o tratamento de alterações inflamatórias do esófago
SG11201707525TA (en) 2015-03-30 2017-10-30 Corcept Therapeutics Inc Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
TW391880B (en) 1994-01-31 2000-06-01 Yamanouchi Pharma Co Ltd An oral soluble type compression moulding and its preparation
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) * 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
HUP0501071A3 (en) 2001-03-13 2007-06-28 Penwest Pharmaceutical Co Chronotherapeutic dosage forms
ATE477804T1 (de) * 2001-03-15 2010-09-15 Soligenix Inc Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
CN100346832C (zh) * 2002-02-07 2007-11-07 法玛西雅公司 经粘膜递送的药物剂型
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US9925139B2 (en) 2004-04-22 2018-03-27 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
BRPI1011624A2 (pt) 2009-04-07 2016-03-22 Duocort Pharma Ab composição, métodos para reduzir um ou mais efeitos colaterais da terapia de glicocorticóide, e para tratar ou previnir um padrão de secreção de glicocorticóide endógeno diminuído ou interrompido em um paciente.
CN102933218A (zh) 2010-05-20 2013-02-13 杜奥科特药物公司 糖皮质激素基的组合物的剂量学和施用

Also Published As

Publication number Publication date
AU2005235370A1 (en) 2005-11-03
US10583146B2 (en) 2020-03-10
PT1744730T (pt) 2016-10-07
US8425937B2 (en) 2013-04-23
HUE053248T2 (hu) 2021-06-28
IL178776A0 (en) 2007-02-11
DK1744730T3 (en) 2016-08-29
PT3072507T (pt) 2021-02-23
JP2007533698A (ja) 2007-11-22
SE0401031D0 (sv) 2004-04-22
LT3072507T (lt) 2021-02-25
IL178776A (en) 2013-10-31
WO2005102271A3 (en) 2006-08-03
WO2005102271A2 (en) 2005-11-03
RS55198B1 (sr) 2017-01-31
JP5681679B2 (ja) 2015-03-11
MX344197B (es) 2016-12-08
HRP20161380T1 (hr) 2016-12-02
CN1942176B (zh) 2013-09-18
RS61501B1 (sr) 2021-03-31
JP5149618B2 (ja) 2013-02-20
EP1744730B1 (en) 2016-08-03
DK3072507T3 (da) 2021-02-08
CY1118275T1 (el) 2017-06-28
CN103006592A (zh) 2013-04-03
US20130129823A1 (en) 2013-05-23
HRP20210348T1 (hr) 2021-04-16
US20140242167A1 (en) 2014-08-28
BRPI0510044B8 (pt) 2021-05-25
CN103006592B (zh) 2016-03-02
PL3072507T3 (pl) 2021-07-19
SI3072507T1 (sl) 2021-04-30
EP3072507A1 (en) 2016-09-28
PL1744730T3 (pl) 2017-01-31
CA2564000C (en) 2013-07-02
EP3072507B1 (en) 2020-12-23
ZA200609680B (en) 2008-08-27
JP2012236846A (ja) 2012-12-06
AU2005235370B2 (en) 2011-06-09
HUE030546T2 (en) 2017-05-29
LT1744730T (lt) 2016-10-25
US20080187586A1 (en) 2008-08-07
CA2564000A1 (en) 2005-11-03
CN1942176A (zh) 2007-04-04
MXPA06012011A (es) 2007-04-16
HK1179525A1 (zh) 2013-10-04
ES2600556T3 (es) 2017-02-09
IL227375A (en) 2017-08-31
BRPI0510044A (pt) 2007-10-16
BRPI0510044B1 (pt) 2019-01-29
NZ585340A (en) 2012-04-27
ME02584B (me) 2017-06-20
EP1744730A2 (en) 2007-01-24
ES2857600T3 (es) 2021-09-29
SG188081A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
CY1124074T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια υποκαταστασης γλυκοκορτικοειδων
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ATE450251T1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200501319A1 (ru) Способы лечения боли введением антагониста фактора роста нервов и нестероидного противовоспалительного средства и содержащие их композиции
DE60302348D1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
BR0318269A (pt) composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares
ATE544460T1 (de) Zusammensetzungen und verfahren für eine gesunde schwangerschaft
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
de Campos et al. Smoking modulates gene expression of type I collagen, bone sialoprotein, and osteocalcin in human alveolar bone
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
BR0312929A (pt) Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo
ATE406158T1 (de) Verwendung von vitamin c zur behandlung der charcot-marie-tooth krankheit
Rokohl et al. Socket discomfort in anophthalmic patients—reasons and therapy options
DE602004025936D1 (de) Therapeutische zusammensetzung enthaltend dentritische zellen und ihre verwendung